奥沙利铂联合氟尿嘧啶治疗老年晚期胃癌患者的临床疗效

Clinical efficacy of oxaliplatin combined with fluorouracil in the treatment of elderly patients with advanced gastric cancer

目的探讨奥沙利铂+氟尿嘧啶治疗老年晚期胃癌患者的临床疗效。方法依据治疗方式的不同将102例老年晚期胃癌患者分为伊立替康组(n=47)和奥沙利铂组(n=55),伊立替康组患者接受伊立替康+氟尿嘧啶治疗,奥沙利铂组患者接受奥沙利铂+氟尿嘧啶治疗。比较两组患者的临床疗效、生活质量[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]及不良反应发生情况。结果奥沙利铂组患者的治疗总有效率为41.82%,与伊立替康组患者的38.30%比较,差异无统计学意义(P﹥0.05)。治疗后,两组患者EORTC QLQ-C30各维度评分均高于本组治疗前,且奥沙利铂组患者EORTC QLQ-C30各维度评分均高于伊立替康组,差异均有统计学意义(P﹤0.05)。两组患者贫血、血小板减少、肝功能减退、口腔炎、恶心呕吐、手足综合征发生率比较,差异均无统计学意义(P﹥0.05);奥沙利铂组患者白细胞减少、腹泻及外周神经毒性发生率均低于伊立替康组,差异均有统计学意义(P﹤0.05)。结论奥沙利铂+氟尿嘧啶与伊立替康+氟尿嘧啶两种化疗方案治疗老年晚期胃癌患者的临床疗效相似,但前者白细胞减少、腹泻及外周神经毒性发生率更低,患者的生活质量更好。

Objective To investigate the clinical efficacy of oxaliplatin combined with fluorouracil in the treatment of elderly patients with advanced gastric cancer.Method A total of 102 elderly patients with advanced gastric cancer were divided into irinotecan group(n=47)and oxaliplatin group(n=55)based on different treatment methods.Patients in the irinotecan group received irinotecan+fluorouracil treatment,while patients in the oxaliplatin group received oxaliplatin+fluorouracil treatment.The clinical efficacy,quality of life[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)],and incidence of adverse reactions were compared between two groups.Result The total effective rate in the oxaliplatin group was 41.82%,which was not significantly different with 38.30%in the irinotecan group(P>0.05).After treatment,the scores of all dimensions of EORTC QLQ-C30 in both groups were higher than those before treatment,and the scores of all dimensions of EORTC QLQ-C30 in the oxaliplatin group were higher than those in the irinotecan group,the differences were statistically significant(P<0.05).There were no statistically significant differences in the incidence of anemia,thrombocytopenia,liver dysfunction,stomatitis,nausea and vomiting,and hand foot syndrome between the two groups(P>0.05).The incidence of leukopenia,diarrhea,and peripheral neurotoxicity in the oxaliplatin group were lower than those in the irinotecan group,and the differences were statistically significant(P<0.05).Conclusion The clinical efficacy of oxaliplatin+fluorouracil and irinotecan+fluorouracil chemotherapy regimens in the treatment of elderly patients with advanced gastric cancer are similar,but the former has lower incidence of leukopenia,diarrhea,and peripheral neurotoxicity,and better quality of life for patients.